BlueMountain Capital Management LLC decreased its position in West Pharmaceutical Services, Inc. (NYSE:WST) by 35.0% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 28,356 shares of the medical instruments supplier’s stock after selling 15,281 shares during the quarter. BlueMountain Capital Management LLC’s holdings in West Pharmaceutical Services were worth $2,680,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Vanguard Group Inc. raised its position in West Pharmaceutical Services by 6.5% in the first quarter. Vanguard Group Inc. now owns 6,440,844 shares of the medical instruments supplier’s stock valued at $525,637,000 after purchasing an additional 392,516 shares during the period. BlackRock Inc. raised its position in West Pharmaceutical Services by 7.1% in the second quarter. BlackRock Inc. now owns 6,217,894 shares of the medical instruments supplier’s stock valued at $587,715,000 after purchasing an additional 412,858 shares during the period. JPMorgan Chase & Co. raised its position in West Pharmaceutical Services by 10.1% in the first quarter. JPMorgan Chase & Co. now owns 2,031,582 shares of the medical instruments supplier’s stock valued at $165,798,000 after purchasing an additional 186,692 shares during the period. Bank of New York Mellon Corp raised its position in West Pharmaceutical Services by 1.3% in the second quarter. Bank of New York Mellon Corp now owns 853,482 shares of the medical instruments supplier’s stock valued at $80,671,000 after purchasing an additional 11,166 shares during the period. Finally, Alliancebernstein L.P. raised its position in West Pharmaceutical Services by 0.3% in the first quarter. Alliancebernstein L.P. now owns 840,899 shares of the medical instruments supplier’s stock valued at $68,626,000 after purchasing an additional 2,748 shares during the period. 91.25% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION WARNING: This piece was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.chaffeybreeze.com/2017/09/17/west-pharmaceutical-services-inc-wst-shares-sold-by-bluemountain-capital-management-llc.html.
Shares of West Pharmaceutical Services, Inc. (NYSE WST) opened at 95.91 on Friday. West Pharmaceutical Services, Inc. has a 12 month low of $70.17 and a 12 month high of $99.91. The stock has a market cap of $7.10 billion, a price-to-earnings ratio of 41.16 and a beta of 1.13. The firm has a 50-day moving average price of $87.41 and a 200-day moving average price of $89.29.
West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $0.66 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.01. The company had revenue of $397.60 million for the quarter, compared to analyst estimates of $406.00 million. West Pharmaceutical Services had a net margin of 11.42% and a return on equity of 14.02%. West Pharmaceutical Services’s revenue for the quarter was up 2.5% on a year-over-year basis. During the same quarter last year, the business earned $0.59 EPS. Equities analysts expect that West Pharmaceutical Services, Inc. will post $2.68 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Wednesday, November 1st. Shareholders of record on Wednesday, October 18th will be issued a $0.14 dividend. This represents a $0.56 dividend on an annualized basis and a dividend yield of 0.58%. The ex-dividend date of this dividend is Tuesday, October 17th. This is a positive change from West Pharmaceutical Services’s previous quarterly dividend of $0.13. West Pharmaceutical Services’s dividend payout ratio (DPR) is 22.22%.
A number of analysts have issued reports on WST shares. Zacks Investment Research lowered West Pharmaceutical Services from a “hold” rating to a “sell” rating in a research report on Wednesday, July 19th. Jefferies Group LLC reissued a “hold” rating and issued a $90.00 target price on shares of West Pharmaceutical Services in a research report on Thursday, June 8th. Finally, BidaskClub lowered West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research report on Wednesday, July 5th. Two investment analysts have rated the stock with a sell rating and three have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $98.52.
About West Pharmaceutical Services
West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.
Receive News & Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related companies with MarketBeat.com's FREE daily email newsletter.